drugset / Trial / NCT06126783
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease
Timeline
- Start
- 2023-10-20
- Primary completion
- 2025-09-23
- Completion
- 2025-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teprotumumab | Monoclonal antibody | 20 mg/kg | — |